晚期胃癌转化治疗的难点、焦点与要点

doi:10.16139/j.1007-9610.2019.01.001

摘要/Abstract

中图分类号:

R735.2

朱正纲. 晚期胃癌转化治疗的难点、焦点与要点[J]. 外科理论与实践, 2019, 24(01): 1-5.

[1] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[2] Joo MK, Park JJ, Chun HJ, et al.Recent updates of precision therapy for gastric cancer: Towards optimal tailored management[J]. World J Gastroenterol,2016,22(19):4638-4650.
[3] Fujitani K, Yang HK, Mizusawa J, et al.Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial[J]. Lancet Oncol,2016,17(3):309-318.
[4] Yoshida K, Yamaguchi K, Okumura N, et al.Is conversion therapy possible in stage Ⅳ gastric cancer: the proposal of new biological categories of classification[J]. Gastric Cancer,2016,19(2):329-338.
[5] Yamaguchi K, Yoshida K, Tanaka Y, et al.Conversion therapy for stage Ⅳ gastric cancer-the present and future[J]. Transl Gastroenterol Hepatol,2016,1:50.
[6] Yamaguchi K, Yoshida K, Tanahashi T, et al.The long-term survival of stage Ⅳ gastric cancer patients with conversion therapy[J]. Gastric Cancer,2018,21(2):315-323.
[7] Sato Y, Ohnuma H, Nobuoka T, et al.Conversion therapy for inoperable advanced gastric cancer patients by doce-taxel, cisplatin, and S-1(DCS)chemotherapy: a multi-institutional retrospective study[J]. Gastric Cancer,2017,20(3):517-526.
[8] 陈凜, 郗洪庆, 申伟松. 积极开展对胃癌肝转移的多学科团队综合治疗[J]. 中华胃肠外科杂志,2014,17(2):101-104.
[9] Beom SH, Choi YY, Beak SE, et al.Multidisciplinary treatment for patients with stage Ⅳ gastric cancer: the role of conversion surgery fpllowing chemotherapy[J]. BMC Cancer,2018,18(1):1116-1133.
[10] Basta YL, Baur OL, Dieren SV, et al.Is there a benefit of multidisciplinary cancer team meetings for patients with gastrointestinal malignancies?[J]. Ann Surg Oncol,2016,23(8):2430-2437.
[11] Lundsqaard Hansen M, Fallentin E, Lauridsen C, et al.Computed tomography (CT) perfusion as an early predictive marker for theratment response to neoadjuvant chemotherapy in gastroesophageal junction cancer and gastric cancer-a prospective study[J]. PLoS One,2014,9(5):e97605.
[12] 张欢, 诗涔. 胃癌CT诊断现状及进展[J]. 诊断学理论与实践,2014,13(4):372-376.
[13] Tang L, Li ZY, Li ZW, et al.Evaluating the response of gastric carcinomas to neoadjuvant chemotherapy using iodine concentration on spectral CT: a comparison with pathological regression[J]. Clin Radiol,2015,70(11):1198-1204.
[14] Won E, Shah MA, Schöder H, et al.Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience[J]. J Gastrointest Oncol,2016,7(4),506-514.
[15] Ott K, Fink U, Becker K, et al.Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: Results of a prospective trial[J]. J Clin Oncol,2016,21(24):4604-4610.
[16] Nakamura K, Iwatsuki M, Kurashige J, et al.Circulating tumor cells in gastric cancer[J]. J Cancer Metastasis Treat,2018,4:32.
[17] Komatsu S, Kiuchi J, Imamura T, et al.Circulating microRNAs as a liquid biopsy: a next generation clinical biomarker for diagnosis of gastric cancer[J]. J Cancer Metastasis Treat,2018,4:36-45.
[18] Lee SJ, Lee J, Kim ST, et al.Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer[J]. Int J Biol Markers,2015,30(4):382-386.
[19] Tahara T, Shibata T, Okubo M, et al.Histological evalua-tion of primary lesions are independently associated with prognosis in patients with gastric cancer who receive neoadjuvent chemotherapy[J]. Oncol Lett,2017,13(6):4892-4896.
[20] Cho H, Nakamura J, Asaumi Y, et al.Long-term survival outcomes of advanced gastric cancer patients who achieved a pathological complete response with neoadjuvant chemotherapy: a systematic review of the literature[J]. Ann Surg Oncol,2015,22(3):787-792.
[21] Fujitani K, Mano M, Hirao M, et al.Posttherapy nodal status, not graded histologic response predicts survival after neoadjuvant chemotherapy for advanced gastric cancer[J]. Ann Surg Oncol,2012,19(6):1936-1943.
[22] Smyth EC, Fassan M, Cunningham D, et al.Effect of pathologic tumor response and nodal status on survival in the medical research council adjuvant gastric infusional chemotherapy trial[J]. J Clin Oncol,2016,34(23):2721-2727.
[23] Fukuchi M, Ishiguro T, Ogata K, et al.Prognostic role of conversion surgery for unresectable gastric cancer[J]. Ann Surg Oncol,2015,22(11):3618-3624.
[24] Zurleni T, Gjoni E, Altomare M, et al.Conversion surgery for gastric cancer patients: A review[J]. World J Gastrointest Oncol,2018,10(11):398-409.
[25] Ida S, Watanabe M.Conversion surgery for stage Ⅳ gastric cancer[J]. J Cancer Metastasis Treat,2018,4:22-30.

晚期胃癌转化治疗的难点、焦点与要点

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张吉祥, 谢智华, 综述, 李炜, 姜小清, 审校. 肝内胆管癌的分型和外科治疗热点[J]. 外科理论与实践, 2022, 27(05): 478-482.
[2]	方诚, 夏勇, 王葵, 沈锋. 肝内胆管癌转化治疗现状与展望[J]. 外科理论与实践, 2022, 27(02): 107-112.
[3]	孙惠川. 肝细胞癌转化治疗的现状与展望[J]. 外科理论与实践, 2022, 27(02): 134-138.
[4]	蔡三军. 结肠直肠癌诊治的思考[J]. 外科理论与实践, 2021, 26(04): 297-299.
[5]	张景辉, 徐袁, 印慨. 胃癌腹膜转移的诊断和相关治疗[J]. 外科理论与实践, 2021, 26(01): 28-33.
[6]	张斌忠, 董来荣, 何春华, 王胤达. 阿帕替尼联合替吉奥化疗对照SOX方案一线治疗晚期胃癌的临床研究[J]. 外科理论与实践, 2020, 25(04): 341-343.
[7]	姜松耀, 赵良超, 严晓伟, 胡皆乐, 项明. 紫杉醇腹腔热灌注联合静脉化疗转化治疗晚期胃癌(附1例报告)[J]. 外科理论与实践, 2020, 25(02): 152-154.
[8]	章真, 周梦龙,. 不可切除局部进展期胃癌的术前放、化疗研究[J]. 外科理论与实践, 2017, 22(01): 9-12.
[9]	张俊, 周尘飞, 朱正纲,. 胃癌转化治疗效果的预测与评估[J]. 外科理论与实践, 2017, 22(01): 21-27.
[10]	严超, 燕敏, 朱正纲,. 胃癌腹膜转移的转化治疗策略:新辅助腹腔内联合全身化疗[J]. 外科理论与实践, 2017, 22(01): 28-31.
[11]	朱正纲,. 晚期胃癌转化治疗的理念与临床意义[J]. 外科理论与实践, 2017, 22(01): 1-4.
[12]	陈凛, 李佶阳,. 胃癌肝转移转化治疗的临床研究进展[J]. 外科理论与实践, 2017, 22(01): 5-8.
[13]	施勇, 詹华,. 双环S型法设计乳腺癌手术切口的应用[J]. 外科理论与实践, 2010, 15(03): 273-277.
[14]	李琛 ,朱正纲. 2002年全国胃癌专业委员会外科学组学术研讨会纪要[J]. 外科理论与实践, 2003, 8(01): 81-82+85.
[15]	朱正纲. 术中腹腔内温热化疗在胃癌外科综合治疗中的临床意义[J]. 外科理论与实践, 2000, 5(03): 138-139+142.